Rapid Testing Panel Simultaneously Detects 15 Drugs of Abuse in Urine Within 21 Minutes

Illicit drug use and excessive use of prescription medicine is growing across the US amid a severe opioid crisis. Although overdose fatalities were reported to have declined by nearly 27% in 2024, many individuals first encountered opioids through legitimate prescriptions. Over time, however, a significant shift has occurred toward illicit substances including heroin and highly potent synthetic opioids like fentanyl, which continue to be the primary contributors to overdose cases today. Now, an easy-to-use clinical drug testing panel offers accurate, cost-effective results, along with an extensive cross-reactivity profile, thus reducing the negative impact on patient care.

The DOA Urine MultiPlex from Randox USA (Crumlin, Ireland, UK) is the most advanced rapid testing panel available on the market, providing simultaneous detection of 15 drugs of abuse from urine in 21 minutes. Available on the Evidence MultiSTAT, fully automated multi‑analyte analyzer, powered by patented Biochip Technology, it simultaneously screens for multiple substances to rapidly direct clinicians to the next steps and efficiently progress an effective treatment plan.

The process requires minimal sample preparation, with results in less than 30 minutes. The Biochip is reliable for drug screening, as it provides semi-quantitative concentrations of substances and metabolites. Covering a range of drug classes, including common, prescription, and synthetic drugs, Biochip delivers multi-analyte detection, while eliminating the constraints of batch testing.

The multiplex Clinical Drug Testing Biochip provides clinicians with a semi-quantitative comprehensive drug screen in patients for various medical reasons including but not limited to; those presenting acute overdose symptoms, screening for clinical trial eligibility and recurring prescription management. The preliminary test result can assist clinicians in identifying recent illicit drug use, as part of their clinical management workflow.

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Randox USA for marketing its newest clinical drug testing panel. The Evidence MultiSTAT, which is also FDA cleared, can achieve accurate, results in minutes with minimal risk of human error or cross contamination. Randox provides the detection of common and novel drug classes with the most extensive test menus available covering analytes such as fentanyl and 6‑MAM.

“Trusted across multiple industries, with widespread adoption and notable placements benefiting forensic toxicology, our latest panel broadens access to drug testing across a wide range of clinical and critical care environments, including emergency departments, hospital laboratories, pain management services, behavioral and psychiatric centers, and the criminal justice system to reduce the negative impact on patient care,” said David Ferguson, Chief Operating Officer.

Related Links:
Randox